DAIICHI SANKYO COMPANY,LIMITED [4568.T]
TOKYO, May 11 (Pulse News Wire) – Daiichi Sankyo Company,limited (4568.T) reported its fiscal year 2025 results and outlined its mid-term plan for. Revenue increased significantly due to strong growth in key products such as Enhertu and Datopotamab Deruxtecan.
Core operating profit grew by 15.196%, excluding one-time expenses amounting to ¥1,332 related to loss compensation to a contract manufacturing organization (CMO). In detail, revenue reached ¥18,863, while cost of sales was ¥4,157. Operating expenses, including research and development costs totaling ¥4,329, contributed to an overall operating profit of ¥3,319.
Net income attributable to parent companies stood at ¥2,958. Looking ahead, the company expects continued growth driven by ongoing investments in DXd ADC products and partnerships with AstraZeneca and Merck & Co., Inc. Daiichi Sankyo also highlighted plans to address potential risks associated with future forecasts and regulatory approvals for developmental compounds.
Separately, the firm noted significant regional contributions, particularly from the Americas and EU specialty businesses, alongside strategic collaborations with major pharmaceutical partners.
🟢 Confidence: High AI-translated content.